EN DE
Watch Biocept, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Biocept, Inc (BIOCQ) fair value: what the stock is really worth

As of Oct 14, 2026: fair value (intrinsic value) of Biocept, Inc stock $0.00, price $0.00, upside -0.3%, quality 22 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US09072V6002

BI Biocept, Inc logo Thin data Oct 30, 2026

Biocept, Inc

BIOCQ · US
Low Priority

The stock costs about what our calculation considers fair.

Fair value $0.0003 · Fairly valued (−0.3%)
Mixed Growth (revenue 3y +67.2 %/yr in USD)
Revenue last quarter 90% below a year ago.
Quality 22/100
Loss-making · -124.1% net margin (FY2022)
Negative free cash flow
Trails peers (1/6)
Narrow moat 3/100 · thin data
Thin data
⚠ Thinly traded
Watch Biocept, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$126.60 $0.0001 Fair Value $0.0003 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

60‑month range $0.0001 – $126.60 · the $0.0003 price screens above the $0.0003 fair value. As of Oct 30, 2026.

Follow Biocept in your weekly email

Every Wednesday you see whether Biocept is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States.

Show moreShow less

Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms.

The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer.

It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations.

The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients.

Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Stock analysis

Biocept, Inc (BIOCQ) currently trades at $0.0003, while our model-based Fair Value estimate is $0.0003, so the stock looks roughly fairly valued today (gap 0.3%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 84/100, which puts the data coverage at low.

Quality & growth

The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Biocept, Inc reported revenue of $25.9M in FY2022 versus $5.5M in FY2019, a compound +67.2%/yr. Reported net income was −$32.1M in FY2022.

Key figures

Market cap $788 Micro · EPS (TTM) $−111.70 · Net margin −124% · Return on equity −187% · Return on assets (EBIT) −67.6% · Operating margin −1,038% · Revenue growth (YoY) −89.9% · Free cash flow −$14.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 70% below its 52-week high and 200% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at 0%, BIOCQ screens cheaper than that median.

Quality Score breakdown

Overall quality 22/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 65
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 78
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 61
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−57.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−417.1% (2019) → −123.7% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
not computed

Watch BIOCQ, get fair value alerts →

Compare Biocept, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 125 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 22 · Bottom 25%
Fair Value upside −0.3% · Above median
Profitability
Return on assets −103.9% · Bottom 25%
Net margin (12 months) −124.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −89.9% · Bottom 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 0
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 14
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥142.89 ¥164.66 +15% vs BIOCQ
IQVIA Holdings IQV $271.55 $298.71 +10% vs BIOCQ
Illumina, Inc ILMN $290.06 $297.04 +2% vs BIOCQ
Thermo Fisher Scientific Inc TMO $693.02 $686.04 −1% vs BIOCQ
Danaher Corporation DHR $232.00 $209.18 −10% vs BIOCQ
IDEXX Laboratories, Inc IDXX $575.98 $496.48 −14% vs BIOCQ
Mettler-Toledo International Inc MTD $1,670 $648.30 −61% vs BIOCQ
Agilent Technologies, Inc A $181.15 $64.53 −64% vs BIOCQ
Lonza Group LONN CHF 640.80 CHF 153.50 −76% vs BIOCQ
Waters Corporation WAT $455.98 $107.35 −76% vs BIOCQ

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Biocept, Inc · Fair Value
$0.0003 −0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Biocept, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIOCQ

Frequently asked questions

Is Biocept, Inc (BIOCQ) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.0003 versus the last price from Oct 14, 2026 of $0.0003, about −0% upside (fairly valued).
What is the fair value of BIOCQ?
Our model-based fair value for Biocept, Inc is $0.0003 (as of Oct 30, 2026), built from audited fundamentals. Last price (from Oct 14, 2026): $0.0003.
What is the quality score of BIOCQ?
Biocept, Inc has a Quality Score of 22/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Biocept, Inc (BIOCQ)?
Our model-based price target is the fair value of $0.0003 (as of Oct 30, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Biocept, Inc stock forecast for 2026?
Our models put fair value at $0.0003, about −0% upside versus the last price from Oct 14, 2026 of $0.0003 (fairly valued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of Biocept, Inc (BIOCQ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Biocept, Inc it is $0.0003 per share (as of Oct 30, 2026), against a price of $0.0003. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Biocept, Inc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, BIOCQ trades above its calculated fair value: price $0.0003, fair value $0.0003, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOCQ?
No. The price is what the market pays today ($0.0003); the fair value is what the company's own numbers justify ($0.0003). For Biocept, Inc the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Biocept, Inc worth?
The market values Biocept, Inc at about $788 (market capitalisation, as of Oct 30, 2026). Per share that is $0.0003; our models calculate a fair value of $0.0003 per share.
How solid is the balance sheet of Biocept, Inc (BIOCQ)?
Balance-sheet figures for Biocept, Inc (as of Oct 30, 2026): return on equity −186.9%. They feed the Quality Score of 22/100, which measures business quality independently of the share price.
How far is BIOCQ from its 52-week high?
Biocept, Inc trades at $0.0003, about 70% below its 52-week high of $0.0010 and 200% above the low of $0.0001 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0003 is for.
Which stocks are comparable to Biocept, Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Biocept, Inc stock attractive at the current price?
The data as of Oct 30, 2026: price $0.0003, calculated fair value $0.0003 (−0%), Quality Score 22/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOCQ calculated?
We run Biocept, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0003, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Biocept, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Biocept, Inc (BIOCQ)?
The latest price we hold is from Oct 14, 2026 and stands at $0.0003. Our model-based fair value is $0.0003, about −0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Biocept, Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Biocept, Inc

How large is the market capitalisation of Biocept, Inc (BIOCQ)?
The market capitalisation of Biocept, Inc is $788. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Biocept, Inc (BIOCQ)?
Earnings per share at Biocept, Inc are $−111.70. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Biocept, Inc (BIOCQ)?
The net margin of Biocept, Inc is −124% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Biocept, Inc (BIOCQ)?
The return on equity (ROE) of Biocept, Inc is −187% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Biocept, Inc (BIOCQ)?
On an EBIT basis the return on assets of Biocept, Inc is −67.6% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Biocept, Inc (BIOCQ)?
The operating margin of Biocept, Inc is −1,038% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Biocept, Inc (BIOCQ)?
Revenue at Biocept, Inc is growing −89.9% versus a year earlier (3y avg +67.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Biocept, Inc (BIOCQ) generate?
The free cash flow of Biocept, Inc is −$14.1M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Biocept, Inc (BIOCQ) hold?
Biocept, Inc holds more cash than debt, $788K net (fiscal year 2022). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Biocept, Inc in the live analysis

One click puts Biocept, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.